# Complete Remission of Recurrent Primary Cutaneous Anaplastic Large Cell Lymphoma Following Bexarotene Therapy: A Case Report

## TL;DR

An elderly man with a rare skin lymphoma achieved full recovery using bexarotene after other treatments failed.

## Contribution

This case report demonstrates bexarotene's effectiveness in treating refractory primary cutaneous anaplastic large cell lymphoma.

## Key findings

- Bexarotene treatment led to complete remission in a patient with recurrent pcALCL.
- The patient showed resistance to radiotherapy and topical steroids but responded well to bexarotene.

## Abstract

Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a CD30-positive cutaneous T-cell lymphoma with a generally favorable prognosis. While radiotherapy is effective, recurrence is not uncommon. Herein, we report the case of an 87-year-old man with recurrent pcALCL who achieved complete remission after bexarotene treatment, despite resistance to radiotherapy and topical steroids. This case highlights bexarotene as a promising therapeutic option for refractory pcALCL. Our experience reinforces the potential of bexarotene as a viable treatment for pcALCL, particularly in recurrent or refractory cases where conventional therapies are contraindicated or ineffective.